SCHEMBL2586375

SCHEMBL2586375

COS(=O)(=O)CC(C)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10306587 0.78
SCHEMBL9936065 0.76
SCHEMBL7460269 0.76
SCHEMBL15800899 0.76 TSHR (0.46)
SCHEMBL9131646 0.74 USP2 (0.30)
SCHEMBL12916978 0.72 LMNA (0.44)
SCHEMBL28406593 0.72 ALDH1A1 (0.38)
SCHEMBL12916989 0.72 ALDH1A1 (0.34)
SCHEMBL15912147 0.70 GAA (0.48)
SCHEMBL28018015 0.70 ALDH1A1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720853-B2 PHARMACEUTICAL COMPOSITIONS OF THE 2 CRYSTALLINE FORM OF IMATINIB MESYLATE FOR USE IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA NATCO PHARMA LTD (IN) 2023-06-28 EP disclosed
EP-1720853-B1 NOVEL POLYMORPHIC FORM OF IMATINIB MESYLATE AND A PROCESS FOR ITS PREPARATION NATCO PHARMA LTD (IN) 2015-12-30 EP disclosed
US-8212012-B2 Novobiocin analogues having modified sugar moieties UNIVERSITY OF KANSAS (US) 2012-07-03 US disclosed
US-8212011-B2 Novobiocin analogues UNIVERSITY OF KANSAS (US) 2012-07-03 US disclosed
US-8048883-B2 Chronic Myelogenous Leukemia; crystal form stable at room temperature or higher temperatures up to 120 degrees C. and accelerated stress conditions, freely soluble in water; suspending Imatinib base in isopropanol and adding methane sulfonic acid at room temperature then cooling after reactoion NATCO PHARMA LIMITED (IN) 2011-11-01 US disclosed
US-7960353-B2 Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders UNIVERSITY OF KANSAS (US) 2011-06-14 US disclosed
US-7811998-B2 Novobiocin analogues as anticancer agents UNIVERSITY OF KANSAS (US) 2010-10-12 US disclosed
CN-1922134-B Synthesis of sterically hindered secondary aminoether alcohols EXXONMOBIL RES & ENG CO 2010-05-26 CN disclosed
US-20100105630-A1 NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS UNIVERSITY OF KANSAS (US) 2010-04-29 US disclosed
US-20100048882-A1 Novobiocin Analogues as Anticancer Agents UNIVERSITY OF KANSAS (US) 2010-02-25 US disclosed
US-7622451-B2 Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders UNIVERSITY OF KANSAS (US) 2009-11-24 US disclosed
US-7608594-B2 Novobiocin analogues as anticancer agents UNIVERSITY OF KANSAS (US) 2009-10-27 US disclosed
US-20090187014-A1 Novobiocin Analogues UNIVERSITY OF KANSAS 2009-07-23 US disclosed
US-20090163709-A1 Novobiocin Analogues Having Modified Sugar Moieties NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-06-25 US disclosed
US-20080255138-A1 Novel Polymorphic Form Of Imatinib Mesylate And A Process For Its Preparation NATCO PHARMA LIMITED (IN) 2008-10-16 US disclosed
US-20070270452-A1 Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-11-22 US disclosed
CN-1922134-A Synthesis of sterically hindered secondary aminoether alcohols EXXONMOBIL RES & ENG CO (US) 2007-02-28 CN disclosed
EP-1720853-A1 NOVEL POLYMORPHIC FORM OF IMATINIB MESYLATE AND A PROCESS FOR ITS PREPARATION Natco Pharma Limited (IN) 2006-11-15 EP disclosed
WO-2006054314-A1 POLYMORPHIC FORMS OF IMATINIB MESYLATE NATCO PHARMA LIMITED (IN) 2006-05-26 WO disclosed
WO-2005077933-A1 NOVEL POLYMORPHIC FORM OF IMATINIB MESYLATE AND A PROCESS FOR ITS PREPARATION NATCO PHARMA LIMITED (IN) 2005-08-25 WO disclosed